{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:25:01Z","timestamp":1790036701443,"version":"4.0.1"},"reference-count":137,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":1262,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.virol.2009.11.001","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T13:15:25Z","timestamp":1259327725000},"page":"187-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge"],"prefix":"10.1016","volume":"397","author":[{"given":"Robert B.","family":"Mandell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Koukuntla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.K.","family":"Mogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Carzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Staplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas N.","family":"Vahanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Flick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.virol.2009.11.001_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.virol.2009.11.001_bib2","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.1128\/JVI.00647-07","article-title":"Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells","volume":"81","author":"Abdel-Motal","year":"2007","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/345671","article-title":"Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans","volume":"36","author":"Al-Hazmi","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0882-4010(88)90096-4","article-title":"Viral determinants of virulence for Rift Valley fever (RVF) in rats","volume":"5","author":"Anderson","year":"1988","journal-title":"Microb. Pathog."},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0882-4010(87)90126-4","article-title":"Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats","volume":"2","author":"Anderson","year":"1987","journal-title":"Microb. Pathog."},{"issue":"10","key":"10.1016\/j.virol.2009.11.001_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0264-410X(91)90285-E","article-title":"Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats","volume":"9","author":"Anderson","year":"1991","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.virol.2009.11.001_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4269\/ajtmh.1991.44.475","article-title":"Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance","volume":"44","author":"Anderson","year":"1991","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib8","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1128\/jvi.71.6.4717-4727.1997","article-title":"A retention signal necessary and sufficient for Golgi localization maps to the cytoplasmic tail of a Bunyaviridae (Uukuniemi virus) membrane glycoprotein","volume":"71","author":"Andersson","year":"1997","journal-title":"J. Virol."},{"issue":"Suppl 2","key":"10.1016\/j.virol.2009.11.001_bib9","first-page":"169","article-title":"Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine","volume":"63","author":"Andre","year":"1987","journal-title":"Postgrad. Med. J."},{"issue":"48","key":"10.1016\/j.virol.2009.11.001_bib10","first-page":"392","article-title":"Outbreak of Rift Valley fever, Yemen, August-October 2000","volume":"75","year":"2000","journal-title":"Wkly. Epidemiol. Rec."},{"issue":"9","key":"10.1016\/j.virol.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/JVI.78.9.4552-4560.2004","article-title":"Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor","volume":"78","author":"Babcock","year":"2004","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0924-8579(02)00295-9","article-title":"Rift Valley fever: an uninvited zoonosis in the Arabian peninsula","volume":"21","author":"Balkhy","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11262-005-0035-7","article-title":"Optimization of codon usage of poxvirus genes allows for improved transient expression in mammalian cells","volume":"33","author":"Barrett","year":"2006","journal-title":"Virus Genes"},{"issue":"1-4","key":"10.1016\/j.virol.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01316748","article-title":"Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies","volume":"121","author":"Besselaar","year":"1991","journal-title":"Arch. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.virol.2008.05.033","article-title":"RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses","volume":"378","author":"Billecocq","year":"2008","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2007.01.046","article-title":"Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease","volume":"362","author":"Bird","year":"2007","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib17","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.virol.2009.11.001_bib18","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1128\/jvi.71.12.9427-9433.1997","article-title":"The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity","volume":"71","author":"Bos","year":"1997","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2004.05.025","article-title":"Ebola and Marburg virus-like particles activate human myeloid dendritic cells","volume":"326","author":"Bosio","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.virol.2009.11.001_bib20","series-title":"Digital Image Processing: An algorithmic introduction using Java","year":"2008"},{"issue":"Pt 10","key":"10.1016\/j.virol.2009.11.001_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2009.11.001_bib22","first-page":"229","article-title":"DIVA\u2014a vaccination strategy enabling the detection of field exposure to avian influenza","volume":"119","author":"Capua","year":"2004","journal-title":"Dev. Biol. (Basel)"},{"issue":"15","key":"10.1016\/j.virol.2009.11.001_bib23","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","article-title":"Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge","volume":"26","author":"Chung","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.virol.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"9233","DOI":"10.1128\/JVI.72.11.9233-9246.1998","article-title":"Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity","volume":"72","author":"Ciarlet","year":"1998","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0042-6822(85)90320-4","article-title":"Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus","volume":"144","author":"Collett","year":"1985","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-2659.2008.00053.x","article-title":"FluBlok, a recombinant hemagglutinin influenza vaccine","volume":"2","author":"Cox","year":"2008","journal-title":"Influenza Other Respi. Viruses"},{"key":"10.1016\/j.virol.2009.11.001_bib27","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1016\/j.vaccine.2009.03.043","article-title":"Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease","volume":"27","author":"El-Attar","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2009.11.001_bib28","series-title":"The Bunyaviridae","author":"Elliott","year":"1996"},{"key":"10.1016\/j.virol.2009.11.001_bib29","first-page":"91","article-title":"Bunyaviridae genome structure and gene expression","volume":"169","author":"Elliott","year":"1991","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.virol.2009.11.001_bib30","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.4049\/jimmunol.173.5.3148","article-title":"Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors","volume":"173","author":"Fifis","year":"2004","journal-title":"J. Immunol."},{"issue":"1-2","key":"10.1016\/j.virol.2009.11.001_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2006.07.035","article-title":"Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors","volume":"356","author":"Filone","year":"2006","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.virol.2009.11.001_bib32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/156652405774962263","article-title":"Rift Valley fever virus","volume":"5","author":"Flick","year":"2005","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib33","first-page":"89","article-title":"Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine\u2013TSI-GSD 200","volume":"29","author":"Frank-Peterside","year":"2000","journal-title":"Afr. J. Med. Med. Sci."},{"issue":"22","key":"10.1016\/j.virol.2009.11.001_bib34","doi-asserted-by":"crossref","first-page":"11010","DOI":"10.1128\/JVI.75.22.11010-11016.2001","article-title":"Rotavirus 2\/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1\/Th2-like immune response","volume":"75","author":"Fromantin","year":"2001","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.copbio.2004.10.002","article-title":"Virus-like particles as vaccines and vessels for the delivery of small molecules","volume":"15","author":"Garcea","year":"2004","journal-title":"Curr. Opin. Biotechnol."},{"issue":"12 Suppl","key":"10.1016\/j.virol.2009.11.001_bib36","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1038\/nm1142","article-title":"Exotic emerging viral diseases: progress and challenges","volume":"10","author":"Geisbert","year":"2004","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.20506\/rst.23.2.1500","article-title":"Rift Valley fever","volume":"23","author":"Gerdes","year":"2004","journal-title":"Rev. Sci. Tech."},{"issue":"23","key":"10.1016\/j.virol.2009.11.001_bib38","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1128\/JVI.76.23.12200-12210.2002","article-title":"Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein","volume":"76","author":"Gerrard","year":"2002","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0092-8674(89)90873-8","article-title":"Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells","volume":"59","author":"Gheysen","year":"1989","journal-title":"Cell"},{"issue":"33-34","key":"10.1016\/j.virol.2009.11.001_bib41","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.virol.2009.11.001_bib42","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1128\/JVI.73.5.4465-4469.1999","article-title":"Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies","volume":"73","author":"Goldmann","year":"1999","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.virol.2008.02.006","article-title":"Immunization with Toscana virus N-Gc proteins protects mice against virus challenge","volume":"375","author":"Gori Savellini","year":"2008","journal-title":"Virology"},{"issue":"1-2","key":"10.1016\/j.virol.2009.11.001_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0264-410X(01)00266-3","article-title":"C3d enhancement of neutralizing antibodies to measles hemagglutinin","volume":"20","author":"Green","year":"2001","journal-title":"Vaccine"},{"issue":"60-65","key":"10.1016\/j.virol.2009.11.001_bib45","article-title":"Virus-like particles; passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0042-6822(03)00372-6","article-title":"Enhancement of mucosal immune responses by chimeric influenza HA\/SHIV virus-like particles","volume":"313","author":"Guo","year":"2003","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.virol.2009.11.001_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0960-9822(02)00482-7","article-title":"Codon usage limitation in the expression of HIV-1 envelope glycoprotein","volume":"6","author":"Haas","year":"1996","journal-title":"Curr. Biol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.virol.2008.12.011","article-title":"Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses","volume":"385","author":"Habjan","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.virol.2009.11.001_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1743-422X-2-42","article-title":"Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins","volume":"2","author":"Haferkamp","year":"2005","journal-title":"Virol. J."},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib51","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1128\/jvi.64.6.2653-2659.1990","article-title":"Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system","volume":"64","author":"Haffar","year":"1990","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib52","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0042-6822(03)00467-7","article-title":"Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core","volume":"314","author":"Hammonds","year":"2003","journal-title":"Virology"},{"issue":"9447","key":"10.1016\/j.virol.2009.11.001_bib53","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib54","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/aid.1991.7.17","article-title":"Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines","volume":"7","author":"Haynes","year":"1991","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.vaccine.2008.11.011","article-title":"Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge","volume":"27","author":"Haynes","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib57","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort. J. Vet. Res."},{"issue":"7-8","key":"10.1016\/j.virol.2009.11.001_bib58","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0264-410X(98)00317-X","article-title":"Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles","volume":"17","author":"Jiang","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0959-440X(00)00073-7","article-title":"Structures of virus and virus-like particles","volume":"10","author":"Johnson","year":"2000","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"9574","key":"10.1016\/j.virol.2009.11.001_bib60","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib61","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/QAD.0b013e32802f7d7c","article-title":"Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection","volume":"21","author":"Kan","year":"2007","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.virol.2009.11.001_bib62","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","article-title":"A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up","volume":"116","author":"Kark","year":"1982","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0264-410X(85)90060-X","article-title":"A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection","volume":"3","author":"Kark","year":"1985","journal-title":"Vaccine"},{"issue":"42-43","key":"10.1016\/j.virol.2009.11.001_bib64","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1016\/j.vaccine.2006.06.031","article-title":"Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors","volume":"24","author":"Khanam","year":"2006","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.virol.2009.11.001_bib65","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1128\/jvi.71.9.6706-6713.1997","article-title":"Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks","volume":"71","author":"Kobasa","year":"1997","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib66","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/nar\/12.2.857","article-title":"Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs","volume":"12","author":"Kozak","year":"1984","journal-title":"Nucleic Acids Res."},{"issue":"5956","key":"10.1016\/j.virol.2009.11.001_bib67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/308241a0","article-title":"Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo","volume":"308","author":"Kozak","year":"1984","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.virol.2009.11.001_bib68","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1093\/nar\/15.20.8125","article-title":"An analysis of 5\u2032-noncoding sequences from 699 vertebrate messenger RNAs","volume":"15","author":"Kozak","year":"1987","journal-title":"Nucleic Acids Res."},{"issue":"1-2","key":"10.1016\/j.virol.2009.11.001_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)01056-9","article-title":"Pushing the limits of the scanning mechanism for initiation of translation","volume":"299","author":"Kozak","year":"2002","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.virol.2009.11.001_bib70","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3201\/eid1408.080082","article-title":"Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya","volume":"14","author":"LaBeaud","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2009.11.001_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol. J."},{"issue":"13","key":"10.1016\/j.virol.2009.11.001_bib72","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1128\/JVI.77.13.7527-7538.2003","article-title":"Importance of Vp1 calcium-binding residues in assembly, cell entry, and nuclear entry of simian virus 40","volume":"77","author":"Li","year":"2003","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virol.2009.11.001_bib73","doi-asserted-by":"crossref","first-page":"e2273","DOI":"10.1371\/journal.pone.0002273","article-title":"Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine","volume":"3","author":"Li","year":"2008","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1016\/j.virol.2009.11.001_bib74","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1128\/JVI.78.14.7344-7351.2004","article-title":"Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles","volume":"78","author":"Licata","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2009.11.001_bib75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-5-82","article-title":"Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins","volume":"5","author":"Liu","year":"2008","journal-title":"Virol. J."},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib76","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.vaccine.2007.11.092","article-title":"Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV","volume":"26","author":"Lokugamage","year":"2008","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.virol.2009.11.001_bib77","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib78","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4269\/ajtmh.1988.39.593","article-title":"Isolation of a newly recognized Bunyamwera serogroup virus from a febrile human in Panama","volume":"39","author":"Mangiafico","year":"1988","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"5947","key":"10.1016\/j.virol.2009.11.001_bib79","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib80","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","article-title":"The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies","volume":"73","author":"Meegan","year":"1979","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"11","key":"10.1016\/j.virol.2009.11.001_bib81","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.1131929100","article-title":"Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection","volume":"100","author":"Murata","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib82","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus","volume":"385","author":"Naslund","year":"2009","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib83","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acta. Pathol. Microbiol. Immunol. Scand. [C]"},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","article-title":"Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans","volume":"3","author":"Niklasson","year":"1985","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.virol.2009.11.001_bib86","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"issue":"21","key":"10.1016\/j.virol.2009.11.001_bib87","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1128\/JVI.01362-06","article-title":"Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding","volume":"80","author":"Overby","year":"2006","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.virol.2009.11.001_bib88","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/JVI.02655-06","article-title":"The glycoprotein cytoplasmic tail of Uukuniemi virus (Bunyaviridae) interacts with ribonucleoproteins and is critical for genome packaging","volume":"81","author":"Overby","year":"2007","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.virol.2009.11.001_bib89","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1128\/JVI.00767-07","article-title":"The cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particles","volume":"81","author":"Overby","year":"2007","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2009.11.001_bib90","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/088922200309368","article-title":"Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques","volume":"16","author":"Paliard","year":"2000","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"11","key":"10.1016\/j.virol.2009.11.001_bib91","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/JVI.00207-09","article-title":"Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge","volume":"83","author":"Perrone","year":"2009","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virol.2009.11.001_bib92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-3542(86)90024-0","article-title":"Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator","volume":"6","author":"Peters","year":"1986","journal-title":"Antiviral. Res."},{"issue":"1-2","key":"10.1016\/j.virol.2009.11.001_bib93","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01311021","article-title":"Experimental Rift Valley fever in rhesus macaques","volume":"99","author":"Peters","year":"1988","journal-title":"Arch. Virol."},{"issue":"1-2","key":"10.1016\/j.virol.2009.11.001_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib95","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vaccine.2008.10.036","article-title":"Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site","volume":"27","author":"Remond","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.virol.2009.11.001_bib96","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1128\/jvi.66.7.4003-4012.1992","article-title":"Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine","volume":"66","author":"Rovinski","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2009.11.001_bib97","series-title":"Virology","article-title":"Orbiviruses and their replication","author":"Roy","year":"2000"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib98","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.4.1.5559","article-title":"Virus-like particles as a vaccine delivery system: myths and facts","volume":"4","author":"Roy","year":"2008","journal-title":"Hum. Vaccin."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrmicro2052","article-title":"Prospects for improved bluetongue vaccines","volume":"7","author":"Roy","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"1-2","key":"10.1016\/j.virol.2009.11.001_bib100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000150482","article-title":"Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen","volume":"39","author":"Schirmbeck","year":"1996","journal-title":"Intervirology"},{"key":"10.1016\/j.virol.2009.11.001_bib101","first-page":"1581","article-title":"Bunyaviridae: the viruses and their replication","volume":"2","author":"Schmaljohn","year":"2001"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib102","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","article-title":"Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins","volume":"170","author":"Schmaljohn","year":"1989","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.virol.2009.11.001_bib103","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JVI.76.8.3952-3964.2002","article-title":"Requirements for budding of paramyxovirus simian virus 5 virus-like particles","volume":"76","author":"Schmitt","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2009.11.001_bib104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-59745-393-6_10","article-title":"Analysis of glycoproteins of viruses in the family Bunyaviridae","volume":"379","author":"Shi","year":"2007","journal-title":"Methods Mol. Biol."},{"issue":"16","key":"10.1016\/j.virol.2009.11.001_bib105","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1128\/JVI.00579-06","article-title":"Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis","volume":"80","author":"Shi","year":"2006","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.virol.2009.11.001_bib106","doi-asserted-by":"crossref","first-page":"10151","DOI":"10.1128\/JVI.00573-07","article-title":"Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis","volume":"81","author":"Shi","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2009.11.001_bib107","doi-asserted-by":"crossref","DOI":"10.1099\/vir.0.013540-0","article-title":"Functional Analysis of the Bunyamwera Orthobunyavirus Gc Glycoprotein","author":"Shi","year":"2009","journal-title":"J. Gen. Virol."},{"issue":"12","key":"10.1016\/j.virol.2009.11.001_bib108","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0812.020195","article-title":"Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01","volume":"8","author":"Shoemaker","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2009.11.001_bib109","series-title":"Hepatitis B vaccines in clinical practice","first-page":"83","article-title":"Survey of licensed hepatitis B vaccines and their production processes","author":"Sitrin","year":"1993"},{"issue":"7","key":"10.1016\/j.virol.2009.11.001_bib110","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1128\/jvi.71.7.5549-5559.1997","article-title":"Mutagenesis analysis of the murine leukemia virus matrix protein: identification of regions important for membrane localization and intracellular transport","volume":"71","author":"Soneoka","year":"1997","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.virol.2009.11.001_bib111","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"issue":"6 Pt 2","key":"10.1016\/j.virol.2009.11.001_bib112","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1083\/jcb.135.6.1841","article-title":"Targeting of Moloney murine leukemia virus gag precursor to the site of virus budding","volume":"135","author":"Suomalainen","year":"1996","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib113","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/jvi.64.4.1549-1555.1990","article-title":"Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment","volume":"64","author":"Suzich","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2009.11.001_bib114","series-title":"Infectious diseases of livestock with special reference to South Africa","article-title":"Rift Valley fever","author":"Swanepoel","year":"2003"},{"issue":"23","key":"10.1016\/j.virol.2009.11.001_bib115","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib116","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.7.4.417","article-title":"Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses","volume":"7","author":"Swenson","year":"2008","journal-title":"Expert. Rev. Vaccines"},{"key":"10.1016\/j.virol.2009.11.001_bib117","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1743-422X-3-70","article-title":"Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses","volume":"3","author":"Szecsi","year":"2006","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.virol.2009.11.001_bib118","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1521-6616(03)00120-7","article-title":"Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers","volume":"108","author":"Tacket","year":"2003","journal-title":"Clin. Immunol."},{"issue":"37","key":"10.1016\/j.virol.2009.11.001_bib119","doi-asserted-by":"crossref","first-page":"21437","DOI":"10.1074\/jbc.270.37.21437","article-title":"Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse","volume":"270","author":"Thall","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.virol.2009.11.001_bib120","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.297.14.1577","article-title":"Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial","volume":"297","author":"Treanor","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.virol.2009.11.001_bib121","series-title":"Fed Register","first-page":"13241","article-title":"Agricultural Bioterrorism Protection Act of 2002; possession, use, and transfer of biological agents and toxins","year":"2005"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","article-title":"Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation","volume":"52","author":"Vialat","year":"1997","journal-title":"Virus Res."},{"issue":"4","key":"10.1016\/j.virol.2009.11.001_bib123","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack","year":"2008","journal-title":"Vaccine"},{"issue":"49-50","key":"10.1016\/j.virol.2009.11.001_bib124","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.virol.2009.11.001_bib125","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"25-26","key":"10.1016\/j.virol.2009.11.001_bib126","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1016\/j.vaccine.2004.01.063","article-title":"Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection","volume":"22","author":"Warfield","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib127","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4049\/jimmunol.175.2.1184","article-title":"Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection","volume":"175","author":"Warfield","year":"2005","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.virol.2009.11.001_bib128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/14760584.4.3.429","article-title":"Filovirus-like particles as vaccines and discovery tools","volume":"4","author":"Warfield","year":"2005","journal-title":"Expert. Rev. Vaccines"},{"issue":"Suppl 2","key":"10.1016\/j.virol.2009.11.001_bib129","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0042-6822(88)90174-2","article-title":"Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins","volume":"166","author":"Wasmoen","year":"1988","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib131","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/JVI.78.2.999-1005.2004","article-title":"Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics","volume":"78","author":"Watanabe","year":"2004","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.virol.2009.11.001_bib132","first-page":"169","article-title":"Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania, December 2006-April 2007","volume":"82","year":"2007","journal-title":"Wkly. Epidemiol. Rec."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib133","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2006.03.021","article-title":"Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies","volume":"351","author":"Ye","year":"2006","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib134","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1073\/pnas.82.6.1618","article-title":"Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon","volume":"82","author":"Yoshinaka","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.virol.2009.11.001_bib135","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.virol.2004.07.009","article-title":"Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle","volume":"327","author":"Young","year":"2004","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virol.2009.11.001_bib136","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymeth.2006.05.024","article-title":"Virus-like particles: designing an effective AIDS vaccine","volume":"40","author":"Young","year":"2006","journal-title":"Methods"},{"issue":"6","key":"10.1016\/j.virol.2009.11.001_bib137","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1128\/JVI.73.6.4972-4982.1999","article-title":"Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability","volume":"73","author":"Zhou","year":"1999","journal-title":"J. Virol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268220900693X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268220900693X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:03:52Z","timestamp":1758585832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004268220900693X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S004268220900693X"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2009.11.001","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2009.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}